Nature Reviews Drug Discovery

The 60-year evolution of lipid nanoparticles for nucleic acid delivery - Nature Reviews Drug Discovery Lipid nanoparticle-based systems are increasingly being utilized for the delivery of nucleic acid-based vaccines and therapeutics. In this Perspective, Cullis and Felgner trace the evolution of these ...

For readers interested in lipid nanoparticles for delivery of nucleic acids, here's a Perspective by Cullis and Felgner
www.nature.com/articles/s41...
rdcu.be/ezlLM

Screenshot of article

Our latest research highlight covers a paper in Science on an in vivo CAR-T cell therapy platform based on mRNA-loaded lipid nanoparticles nature.com/articles/d41...

AbbVie recently paid $2.1 billion to buy the company that developed the platform, Capstan Therapeutics nature.com/articles/d41...

How multispecific molecules are transforming pharmacotherapy - Nature Reviews Drug Discovery Multispecific drugs are designed to engage two or more entities to exert their pharmacological effect. This Perspective discusses how a new wave of FDA-approved multispecific molecules have been trans...

How multispecific molecules are transforming pharmacotherapy
www.nature.com/articles/s41...
rdcu.be/ezbK0

This new article by Raymond Deshaies discusses how a wave of drugs designed to engage two or more entities are overcoming development barriers such as toxicity, rapid clearance and redundancy

Table of contents for August issue

Our August issue is live! Read about antibody-drug conjugates with dual payloads, GLP-1-based therapies, biomarker-guided drug development for neurodegenerative disorders, immunomodulators targeting the aryl hydrocarbon receptor and more here www.nature.com/nrd/volumes/...

Trends in the development of cellular and gene therapy in China www.nature.com/articles/d41...

This new article analyses the landscape for cell and gene therapy in China, including the characteristics of products in clinical trials and those that have been approved

Oncolytic viruses in development

Oncolytic virus drought continues, as Replimune fails to secure FDA cancer approval
www.nature.com/articles/d41...

In vivo CAR immune cell products in development

In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics www.nature.com/articles/d41...

Advances in the treatment of systemic lupus erythematosus - Nature Reviews Drug Discovery Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations. This Review discusses advances in understanding its immunopathogenesis, the evolution of target...

Review
@natrevdrugdiscov.nature.com
Advances in the treatment of systemic lupus erythematosus #lupus #SLE
nature.com/articles/s41...

Kinase gene alterations in cancer

For readers interested in anticancer drugs, this Review in the July issue discusses progress and challenges in the development of tumour-agnostic kinase inhibitors
www.nature.com/articles/s41...
rdcu.be/eybm4

Therapeutic strategies for lupus

Advances in the treatment of systemic lupus erythematosus www.nature.com/articles/s41...
rdcu.be/exh97

This new Review covers approaches aimed at specific immune pathways and efforts to restore immune homeostasis, such as CAR T cell therapies to eliminate B cells and regulatory T cell therapies

China outlicensing trends

The rise of China’s pharmaceutical industry from 2015–2024 nature.com/articles/d41...

This new article analyses the growth in drug innovation in China, the underlying environmental factors and strategic trends such as the outlicensing of assets originating in Chinese companies

Roadmap for N-of-1 therapies

For readers interested in N-of-1 therapies, this recent article from discusses progress and a roadmap for their development nature.com/articles/s41...
rdcu.be/ewDqP

Screenshot of article

Building on the momentum of N-of-1 base editor therapies for rare diseases www.nature.com/articles/d41...

Rebecca Ahrens-Nicklas at the Children’s Hospital of Philadelphia discusses her groundbreaking application of a gene-editing therapy for an ultra-rare urea cycle disorder

CRISPR-based editors

CRISPR-based therapeutic genome editing for inherited blood disorders nature.com/articles/s41...
rdcu.be/ewvcJ

This new Review discusses the application of genome editing technologies including nucleases, base editors and prime editors to treat patients with inherited haematological disorders

Chemical modifications of RNA

RNA chemistry and therapeutics www.nature.com/articles/s41...
rdcu.be/ewkq0

This new Review covers synthetic methods applied to RNA therapeutics in multiple classes and chemical modification strategies being used to enhance their properties
@yizhoudonglab.bsky.social

Screenshot of article

FDA approves first factor XIIa inhibitor, for hereditary angioedema nature.com/articles/d41...

CSL's first-in-class monoclonal antibody therapy garadacimab provides a once-monthly preventative option

If you enjoyed our RNA splicing collection, this @natrevdrugdiscov.nature.com Review may be of interest:
Protein isoform-centric therapeutics: expanding targets and increasing specificity go.nature.com/44HDClo

Unmet needs in vaccine development Discover the world’s best science and medicine | Nature.com

#Medsky🧪 #IDsky #drugsdevelopment #immunosky #publichealth Mortality, prevalence , burden of #infectiousdiseases & Unmet needs in #vaccine development @natrevdrugdiscov.nature.com

www.nature.com/articles/d41...

Screenshot of article

FDA approves twice-yearly capsid inhibitor for HIV prevention
www.nature.com/articles/d41...

Unmet needs in vaccine development

Unmet needs in vaccine development www.nature.com/articles/d41...
This new article examines the gap between infectious disease burden and vaccine availability, underscoring the role of vaccine innovation and proposing actions to advance equitable vaccine research and development

US biosimilars market penetration

The US biosimilars market after one decade www.nature.com/articles/d41...

This new article analyses policies and strategies affecting biosimilar adoption in the US, and considers the outlook for the development of the biosimilar market in the next five years

Screenshot of news story

A first-in-class drug for the inflammatory lung disease bronchiectasis that could be approved by the FDA in the next few weeks is anticipated to have peak sales of more than $4 billion. Find out more in this news story in the July issue www.nature.com/articles/d41...

Screenshot of news article

Dual-payload antibody-drug conjugates move into first oncology clinical trials nature.com/articles/d41...

A rapidly growing cohort of companies are exploring if two different warheads may be better than one on ADCs, potentially unlocking durable anticancer efficacy

Trends for oral drug candidates

The changing landscape of medicinal chemistry optimization www.nature.com/articles/s41...
rdcu.be/evaV5

This new article analyses oral drug candidates and their corresponding hit and lead compounds from recent years and from the early 2000s, and discusses the implications of the observed trends

Screenshot of July issue contents

Our July issue is live! Read about neutrophil-targeting drugs, tumour-agnostic kinase inhibitors, computational drug repurposing, antifibrotic therapies and more here www.nature.com/nrd/volumes/...

Targeting the Hippo pathway in cancer Nature Reviews Drug Discovery - The Hippo signalling pathway fulfils a vital role in the regulation of tissue homeostasis and organ development and its dysregulation is associated with several...

Pleased to share our review in @natrevdrugdiscov.nature.com. 20+ years after the Hippo pathway was discovered in Drosophila, the first targeted therapies are in clinical trials for cancer and heart disease.

Big thanks to co-author Tracy Tang from Vivace Therapeutics. #TEADinhibitors

rdcu.be/et2NL

Targets in gram-negative bacteria

For readers interested in novel therapeutic targets to combat Gram-negative bacterial infections, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/euuNs

Screenshot of article

Our latest research highlight covers a paper in Science Translational Medicine on a prodrug based on a host defence peptide that is activated at sites of infection and shows potent antimicrobial activity in mouse models of Gram-negative bacterial infection www.nature.com/articles/d41...

Secondary pharmacology screening panel composition

For readers interested in secondary pharmacology screening of small-molecule drug candidates and its impact on drug safety, here's a comprehensive discussion of the state of the art
www.nature.com/articles/s41...
rdcu.be/eujQ4

Enzymes in screening panels

Two correspondence articles in the June issue discuss the inclusion of enzymes in secondary pharmacology screening panels to reduce the risks of off-target toxicities emerging for investigational drugs
rdcu.be/eujQn
rdcu.be/eujQH